ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Clinical Evolution of Patients with De Novo DSA After Kidney Transplantation

C. López del Moral1, N. Lachmann2, S. Hergovits2, D. Stauch2, A. Akifova3, M. Naik3, B. Osmanodja3, D. Schmidt3, K. Budde3

1Nephrology department-IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Institute for Transfusion Medicine, HLA-Laboratory, Charité - Universitätsmedizin, Berlin, Germany, 3Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Germany

Meeting: 2022 American Transplant Congress

Abstract number: 116

Keywords: Antibodies, Graft failure, Kidney transplantation, Proteinuria

Topic: Clinical Science » Kidney » 47 - Kidney Complications: Immune Mediated Late Graft Failure

Session Information

Session Name: Kidney Complications: Chronic Antibody Mediated Rejection & Immune Mediated Late Graft Failure

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 6:00pm-6:10pm

Location: Hynes Room 302

*Purpose: De novo donor-specific antibodies(dnDSA) are related to antibody-mediated rejection(ABMR), but the evolution of patients after dnDSA is variable and not always ABMR and graft dysfunction occur. Regular laboratory values can predict graft function and should be considered as reliable endpoints. We performed this study to assess the situation of the patients after dnDSA and address potential predictors of graft failure.

*Methods: A retrospective analysis including 400 kidney transplant recipients with dnDSA against the last graft until 31/05/2021 was performed. Laboratory values at dnDSA first occurrence were collected, and the dates of doubling creatinine, ≥30% eGFR decline, proteinuria ≥500 and ≥1000 mg/g in at least two consecutive determinations and before graft failure were registered from dnDSA occurrence. Patients were classified as ‘completely stable’ (no graft loss, no ≥30% reduction in eGFR, no proteinuria ≥500 mg/g) at 5 years post-dnDSA.

*Results: The median follow-up period was 9.7 years (7.2-12.2). At dnDSA first occurrence, the median value of proteinuria was 182.0 mg/g, eGFR 41.0 ml/min and creatinine 1.6 mg/dl. Creatinine doubled after a median of 2.8 years (1.5-5.0), and the time from doubling creatinine to graft failure was 1.0 years (0.4-2.9). Analyzing a ≥30% decline in eGFR, the time from first occurrence of dnDSA to this event was 2.0 years (0.6-4.2), with a median of 2.0 years (0.8-3.2) to graft loss. The median time from proteinuria ≥500mg/g and ≥1000mg/g to graft failure was identical (1.8 years). The 5-year incidence of renal outcomes is shown in figure 1. At 5 years post-dnDSA, 115 of patients were ‘completely stable’.

*Conclusions: A relevant (28.7%) proportion of patients has a ‘completely stable’ clinical course after 5 years post-dnDSA. Proteinuria is a marker of progression in our patients. Doubling creatinine is a predictor of graft dysfunction as can also be a ≥30% decline in eGFR, appearing earlier after dnDSA.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Moral CLópezdel, Lachmann N, Hergovits S, Stauch D, Akifova A, Naik M, Osmanodja B, Schmidt D, Budde K. Clinical Evolution of Patients with De Novo DSA After Kidney Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-evolution-of-patients-with-de-novo-dsa-after-kidney-transplantation/. Accessed March 26, 2023.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2023 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences